YB4P.F Savara Inc

Healthcare Biotechnology Frankfurt Exchange
4.30 EUR
Close of Nov 13, 2026
3.54 5.90
Market cap
EUR 950M
P/E
-
P/B
9.91x
ROE
-149.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is YB4P.F undervalued?

Graham number

The Graham number of Savara Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Savara Inc fundamental analysis

No fundamental analysis for Savara Inc yet.

Savara Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.

Full company profile